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The SMYD (SET and MYND domain) family of lysine methyltransferases harbor a unique structure in
which the methyltransferase (SET) domain is intervened by a zinc ﬁnger protein–protein interaction
MYND domain. SMYD proteins methylate both histone and non-histone substrates and participate in
diverse biological processes including transcriptional regulation, DNA repair, proliferation and apoptosis.
Smyd1 is unique among the ﬁve family members in that it is speciﬁcally expressed in striated muscles.
Smyd1 is critical for development of the right ventricle in mice. In zebraﬁsh, Smyd1 is necessary for
sarcomerogenesis in fast-twitch muscles. Smyd1 is expressed in the skeletal muscle lineage throughout
myogenesis and in mature myoﬁbers, shuttling from nucleus to cytosol during myoblast differentiation.
Because of this expression pattern, we hypothesized that Smyd1 plays multiple roles at different stages of
myogenesis. To determine the role of Smyd1 in mammalian myogenesis, we conditionally eliminated
Smyd1 from the skeletal muscle lineage at the myoblast stage using Myf5cre. Deletion of Smyd1 impaired
myoblast differentiation, resulted in fewer myoﬁbers and decreased expression of muscle-speciﬁc genes.
Muscular defects were temporally restricted to the second wave of myogenesis. Thus, in addition to the
previously described functions for Smyd1 in heart development and skeletal muscle sarcomerogenesis,
these results point to a novel role for Smyd1 in myoblast differentiation.
& 2015 Elsevier Inc. All rights reserved.1. Introduction
Congenital myopathies and muscular dystrophies arise from
mutations within genes responsible for diverse aspects of myo-
genesis and myoﬁber homeostasis. Thus, understanding the mo-
lecular genetics of muscle development is paramount to devel-
oping the basic science foundation required to develop cures for
these diseases. Mammalian skeletal myogenesis consists of two
distinct phases producing primary and secondary myoﬁbers, re-
spectively. In mice, the primary/embryonic wave takes place from
embryonic day (E) 10.5 to E12.5 and the secondary/fetal wave
occurs from E14.5 to E17.5 (Biressi et al., 2007b). Primary muscle
ﬁbers ﬁrst appear on E11.5, when a small fraction of embryonic
myoblasts fuse. Secondary ﬁbers are formed through fusion of fetal
myoblasts with each other or with primary ﬁbers. From E15.5Biochemistry, University of
USA.onwards, smaller secondary ﬁbers can be found adjacent to bigger
primary ﬁbers. Fetal myogenesis is also characterized by inception
of innervation (Rossi and Messina, 2014). The myogenic cells that
give rise to these two waves have been well documented to have
distinct characteristics in terms of the genes they express, the
features of the myotubes they produce in vitro and their response
to inhibitors of myogenesis and growth factors (Biressi et al.,
2007b). In general, primary ﬁbers are similar to adult slow-twitch
muscle ﬁbers while secondary ﬁbers exhibit characteristics of
adult fast-twitch muscle ﬁbers (Biressi et al., 2007a).
The SMYD (SET and MYND domain) family of lysine methyl-
transferases is deﬁned by a unique structure in which the me-
thyltransferase (SET) domain is intervened by a zinc ﬁnger pro-
tein–protein interaction MYND domain (Spellmon et al., 2015).
SMYD proteins are implicated in a vast number of biological pro-
cesses including transcriptional activation/repression (Huang
et al., 2006; Xu et al., 2015), DNA repair (Piao et al., 2014), cell cycle
(Cho et al., 2012; Saddic et al., 2010), tumorigenesis (Luo et al.,
2014; Mazur et al., 2014) and apoptosis (Sajjad et al., 2014). Smyd1
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and b isoforms) is restricted to striated muscles; a third c isoform
is expressed in CD8þ T cells (Gottlieb et al., 2002; Hwang and
Gottlieb, 1997). Smyd1 harbors both transcriptional activation and
repression activities and methylates both histone and non-histone
substrates (Rasmussen et al., 2015; Tan et al., 2006). Smyd1 me-
thylates histone H3 at lysine 4, a modiﬁcation associated with
active transcription (Tan et al., 2006), but Smyd1 represses tran-
scription when tethered to DNA by recruitment of HDAC1, -2 or -3
to its MYND domain (Sims et al., 2002). The MYND domain is also
the site of interaction with the muscle-speciﬁc transcription factor
skNAC (Sims et al., 2002), the only transcription factor known to
associate with Smyd1. Smyd1 methylates the cardiac endoplasmic
reticulum stress sensor TRB3, which in turn, serves as a cor-
epressor for Smyd1 (Rasmussen et al., 2015). Expression of Smyd1
in muscle is regulated by a number of factors such as MEF2C, SRF,
Myogenin and HDGF (Li et al., 2009; Phan et al., 2005; Yang and
Everett, 2009). Conventional knockout of Smyd1 in mice results in
embryonic lethality by E10.5 due to failure in right ventricular
development (Gottlieb et al., 2002).
Due to embryonic lethality prior to myogenesis in mice (Got-
tlieb et al., 2002), most knowledge of Smyd1’s function in skeletal
muscle comes from studies in zebraﬁsh (Du et al., 2006; Gao et al.,
2014; Li et al., 2011, 2013; Tan et al., 2006) where it is critical for
sarcomerogenesis in fast-twitch muscles (Just et al., 2011). Smyd1
co-localizes with nascent myosin during sarcomerogenesis and
then to the M-line of mature sarcomeres. Antisense morpholino-
based knock-down of both Smyd1 isoforms in zebraﬁsh embryos
led to severe impairment of myoﬁbrillogenesis in both skeletal and
cardiac muscle. Myosin chaperones Hsp90α1 and UNC45b were up
regulated (Just et al., 2011; Li et al., 2013), suggesting that thick
ﬁlament assembly is impaired in the absence of Smyd1. Smyd1’s
physical interaction with myosin is crucial for proper myoﬁbrillar
arrangement in zebraﬁsh skeletal muscle (Just et al., 2011). These
data indicate that Smyd1 is an important facilitator of
myoﬁbrillogenesis.
Based on gene expression and protein localization, we hy-
pothesized that Smyd1 also plays a role in early myogenesis. In
Xenopus laevis, chick and zebraﬁsh embryos, Smyd1 is expressed in
the somites at the onset of myogenesis (Du et al., 2006; Gottlieb
et al., 2002; Just et al., 2011; Kawamura et al., 2008). Expression
persists throughout myogenesis and in mature myoﬁbers. The
subcellular localization of Smyd1 during myogenesis has been
studied in vitro using mouse C2C12 myoblasts (Sims et al., 2002).
In C2C12 cells, Smyd1 expression increases tremendously during
the transition from myoblast to myotubes (Berkholz et al., 2014; Li
et al., 2009; Sims et al., 2002). Smyd1 localizes to the nucleus and
cytoplasm of myoblasts; however, after fusion, Smyd1 mostly re-
sides in the cytoplasm of myotubes (Berkholz et al., 2014; Sims
et al., 2002). This nuclear to cytoplasmic translocation of Smyd1
during myoblast differentiation is regulated by sumoylation—as
inhibition of sumoylation resulted in nuclear accumulation of
Smyd1 and reduced terminal differentiation (Berkholz et al., 2014).
These data suggest a role for Smyd1 in the formation of myotubes
during embryogenesis.
The purpose of this study was to elucidate Smyd1’s role during
skeletal myogenesis in mice. To this end, we conditionally elimi-
nated Smyd1 from early muscle precursor cells using Myf5cre. De-
letion of Smyd1 in early myoblasts did not affect proliferation, but
instead impaired differentiation, resulting in fewer muscle ﬁbers
and decreased expression of skeletal muscle-speciﬁc genes. Mus-
cular defects were temporally restricted to the second myogenic
wave. Thus, in addition to the previously described functions for
Smyd1 in expansion of second heart ﬁeld progenitor cells, ma-
turation of cardiomyocytes, antagonizing cardiomyocyte stress
responses and skeletal muscle sarcomerogenesis, these resultspoint to a novel role for Smyd1 in myoblast differentiation.2. Results
2.1. Smyd1 expression and subcellular localization during
myogenesis.
A previous analysis of Smyd1 spatial expression during em-
bryogenesis showed Smyd1 mRNA to be expressed very speciﬁ-
cally in the heart and somites of chick embryos by Hamburger and
Hamilton stage 20 (Gottlieb et al., 2002). Similar expression was
reported for zebraﬁsh embryos (Du et al., 2006; Just et al., 2011;
Tan et al., 2006). However, in E10.5 mouse embryos, Smyd1 mRNA
was detected in the heart, but not the somites (Gottlieb et al.,
2002). To reconcile this difference, we assayed the spatial ex-
pression of Smyd1 mRNA in mouse embryos at E9.5 by in situ
hybridization. In agreement with chick and zebraﬁsh experiments,
Smyd1 mRNA was very speciﬁcally expressed in both somites and
heart (Fig. 1A). These data conﬁrm that Smyd1 is a striated muscle-
speciﬁc methyltransferase with initial onset of expression in the
skeletal muscle linage occurring prior to the appearance of
myoﬁbers.
Myf5cre mice harbor an IRES-cre knock-in within the 5’ UTR of
the Myf5 gene (Haldar et al., 2007); therefore, cre expression
should be restricted to somitic myoblasts and absent from cardiac
lineages. We conﬁrmed this activity using the Rosa26YFP reporter.
Cre-induced recombination of loxP sites occurred very speciﬁcally
in the somites and not in the heart (the other site of Smyd1 ex-
pression) (Fig. 1B). These data illustrate the utility of this genetic
cross to delete Smyd1 at the earliest stage of its expression in the
skeletal muscle lineage without affecting heart development.
It was reported that the subcellular localization of Smyd1
changes during C2C12 myoblast differentiation (Berkholz et al.,
2014; Sims et al., 2002); however, this has yet to be observed for
endogenous Smyd1 during myogenesis in vivo. First, we conﬁrmed
previous reports showing export of Smyd1 from nucleus to cytosol
during C2C12 differentiation. Smyd1 localized to both the nucleus
and cytoplasm in undifferentiated C2C12 myoblasts (Fig. 1C). After
5 days in differentiation medium, Smyd1 localized primarily to the
cytosol of myotubes (Fig. 1D). Relatively low levels of ﬂuorescence
were still detectable in the nucleus. Thus, while the majority of
Smyd1 protein is cytoplasmic in myotubes, a small fraction re-
mains in the nucleus with the potential to regulate transcription.
Next, we determined spatial and temporal expression of Smyd1
during myogenesis in vivo. Within the myotome at E11.5, Smyd1
and Pax7 did not co-localize (Fig. 1E–I), thus representing distinct
cell populations. In contrast, Smyd1 co-localized with Myogenin
(Myog) in many cells (Fig. 1J–N, white arrowheads in panel M).
Individual cells could be observed expressing Myog, but little to no
Smyd1 (Fig. 1M, yellow arrowheads). Cells expressing high Smyd1
with low Myog are likely newly formed primary ﬁbers (Fig. 1M,
purple arrowheads). Similar results were observed in skeletal
muscle at E16.5 (Fig. 1O–S). At this stage, Smyd1 protein is abun-
dant in the sarcoplasm of all ﬁbers with relatively lower levels in
myonuclei. Smyd1 colocalized with Myog in many newly forming
secondary ﬁbers (Fig. 1R, white arrowheads). A small number of
cells expressed Myog, but little to no Smyd1 (Fig. 1R, yellow ar-
rowheads). Collectively, these data indicate that Smyd1 is down-
stream of Pax7 and Myog, being expressed in Myogþ myoblasts,
but not Pax7þ progenitor cells.
Previous reports showed that Smyd1 localizes to the M-line of
muscle ﬁbers in zebraﬁsh (Just et al., 2011; Li et al., 2011). Indeed
by E15.5 and in adult muscle, Smyd1 exhibited a characteristic
sarcomeric localization pattern with alternating bands of α-actinin
and Smyd1 (Fig. 1T, U). These results are consistent with the
Fig. 1. Smyd1 expression and subcellular localization during myogenesis. (A) Whole mount in situ hybridization for Smyd1 mRNA at E9.5. Smyd1 mRNA is speciﬁcally
localized to the heart (white asterisk) and somites (red arrow). (B) Stereoimage overlay of YFP ﬂuorescence (green) and brightﬁeld.Myf5cre is speciﬁcally active in the somites
(red arrow), but not the heart (white asterisk). (C, D) Immunoﬂuorescence for Smyd1 (green) in undifferentiated C2C12 myoblasts (C) or myotubes after ﬁve days in
differentiation medium (D). (E–I) Immunoﬂuorescence for Smyd1 (green) and Pax7 (red) in the myotome of control (E–H) or Smyd1 CKO (I) embryos at E11.5. (J–N)
Immunoﬂuorescence for Smyd1 (green) and Myog (red) in the myotome of control (J-M) or Smyd1 CKO (N) embryos at E11.5. (O–S) Immunoﬂuorescence for Smyd1 (green)
and Myog (red) in the EDL muscle of control (O–R) or Smyd1 CKO (S) embryos at E16.5. (T, U) Immunoﬂuorescence for Smyd1 (green) and α-actinin (red) in longitudinal
skeletal muscle sections of wild-type embryos at E15.5 (T) and adult soleus muscle (U). Blue, nuclei (DAPI). (M, R) White arrowheads, co-localization of Smyd1 and Myog;
yellow arrowheads, Myogþ Smyd1 cells; purple arrowheads, young ﬁbers with low Myog and high Smyd1. Scale bars are 1 mm (A, B), 50 mm (C, D) and 10 μm (E–U). Ctrl,
control; CKO, conditional knockout.
Table 1
Smyd1 CKO embryos exhibit perinatal lethality.
Stage Embryos Recovered Expected CKOs Observed CKOs
E9.5 20 5 7
E10.5 196 49 49
E11.5 9 2.25 2
E13.5 48 12 10
E14.5 8 2 1
E15.5 142 35.5 30
E16.5 45 11.25 17
E17.5 31 7.75 4 (motionless)
E18.5 16 4 4 (motionless)
*P0 53 13.25 6 (dead)
* P¼0.001, Fisher's Exact Test; CKOs, conditional knockouts; E, embryonic day;
P, postnatal day.
H. Nagandla et al. / Developmental Biology 410 (2016) 86–9788conclusion that the majority of Smyd1 in differentiated ﬁbers lo-
calizes to the M-line.
These data support a working model in which Smyd1 functions
primarily as a nuclear transcriptional regulator during myoblast
proliferation and differentiation. Later, as Smyd1 accumulates in
myotube/myoﬁber sarcoplasm, it serves in sarcomere assembly
and stability. Using Myf5cre, we were able to deplete Smyd1 from
myoblasts, at a time in which the protein is most likely to be af-
fecting the myogenic transcriptional program.
2.2. Smyd1 CKO embryos exhibit perinatal lethality
Embryos from the cross Myf5cre/þ; Smyd1þ / x Smyd1ﬂox/ﬂox;
Rosa26YFP/YFP were recovered at various developmental stages
(Table 1). The expected Mendelian percentage (25%) of CKO em-
bryos were observed at all stages of gestation. However, embryos
Fig. 2. Smyd1 CKO embryos appear normal during the ﬁrst wave of myogenesis. (A–B) Brightﬁeld stereoimages of control (A) and Smyd1 CKO (B) embryos at E11.5. (C–F)
Whole mount in situ hybridization for α-actin mRNA in control (C, E) and Smyd1 CKO (D, F) embryos at E10.5. (G) Measurement of myotome width (somites 7–12) using
images such as illustrated in E and F. No difference was observed (nZ7 embryos/group). (H–R) Results of real-time PCR for myogenic transcription factors (H–L) and markers
of differentiation (M–R) at E11.5. No differences in gene expression were observed (nZ8 embryos/group). Scale bars are 1 mm (A–D) and 200 mm (E, F). Student's t test. Error
bars indicate SEM. Ctrl, control; CKO, conditional knockout.
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pected number of Smyd1 CKO pups were found on the day of birth
(postnatal day 0) and those that were identiﬁed were dead. Thus,
loss of Smyd1 in the myogenic lineage produces perinatal lethality
likely due to inability to breathe.
2.3. Smyd1 CKO embryos appear normal during the ﬁrst wave of
myogenesis
At E11.5, during the ﬁrst wave of myogenesis, Smyd1 CKO em-
bryos were indistinguishable from control embryos (Fig. 2A, B).
In situ hybridization for α-actin showed normal somitogenesis in
Smyd1 CKOs at E10.5 (Fig. 2C–F), with no difference in myotome
width (somites 7–12) between controls and CKOs (Fig. 2G). We
next tested whether loss of Smyd1 affected muscle gene expres-
sion during the ﬁrst wave of myogenesis. At E11.5, the midpoint of
the ﬁrst wave, mRNA expression of major myogenic transcription
factors (Pax3, Pax7, Myf5, Myod1 and Myf6) was equivalent be-
tween control and CKO embryos (Fig. 2H–L). At the same stage,
expression of several genetic markers of differentiated myoﬁbers
(Acta1 (α-actin), Myh3 (embryonic MyHC), Myh7 (slow MyHC),
Myh8 (Fetal MyHC), Ckm (creatine kinase) and Eno3 (β-enolase))
was also equivalent (Fig. 2M–R). These data point to normal in-
itiation of the skeletal myogenesis program in the absence of
Smyd1.
2.4. Smyd1 CKO embryos exhibit reduced muscle mass and sub-
cutaneous edema during the second myogenic wave
As expected, Myf5cre-induced recombination was restricted to
the skeletal muscle lineage, dorsal epidermis and brown adipose
of control and Smyd1 CKO embryos as determined by ﬂuorescencefrom the Rosa26YFP reporter (Fig. 3A–D). Loss of Smyd1 protein was
conﬁrmed by western blot using protein extracts from the body
wall of E16.5 embryos (Fig. 3E). By E15.5, Smyd1 CKO embryos
were easily distinguished from control littermates by dorsal sub-
cutaneous edema (Fig. 3F, G). Transverse tissue sections were
prepared at the level of the forelimbs for H&E staining and im-
munoﬂuorescence. In these sections, the dorsal subcutaneous
edema manifested as a wide region of loose connective tissue
between the skin and back muscles (Fig. 3H, I). This pathology may
be similar to the “amorphous connective tissue” reported in Myf5/
MyoD double knockout mice, which completely lack skeletal
muscle (Rudnicki et al., 1993). Back muscles also appeared di-
minished in H&E sections (Fig. 3H, I). Relative myoﬁber abundance
was determined by immunoﬂuorescence for sarcomeric α-actinin.
Far less α-actinin staining was observed in Smyd1 CKO embryos
(Fig. 3J, K), suggesting reduced muscle mass. Furthermore, in
western blots, Smyd1 CKO embryos exhibited 2.3-fold less total
myosin heavy chain (MyHC) protein than controls (mean pixel
intensity: Ctrl, 35.1076.56 u; CKO, 15.2573.29 u; P¼0.03, Stu-
dent’s t-test) (Fig. 3E). These data indicate reduced muscle mass
during the second wave of myogenesis in the absence of Smyd1.
2.5. Fewer muscle ﬁbers and reduced muscle gene expression during
the second wave of myogenesis
Myoﬁber abundance and organization was assayed by im-
munoﬂuorescence using a pan-MyHC antibody. Longitudinal sec-
tions of the extensor digitorum longus (EDL) muscle showed dis-
organized arrangement of myoﬁbers in Smyd1 CKOs at E16.5
(Fig. 4A, B). Similarly stained transverse sections of EDL muscles
revealed less densely packed myoﬁbers and less anti-MyHC im-
munoreactivity in the Smyd1 CKOs (Fig. 4C, D). Wide-ﬁeld images
Fig. 3. Smyd1 CKO embryos exhibit reduced muscle mass and subcutaneous edema.
(A–D) Overlay of YFP (green) and brightﬁeld stereoﬂuorescence images at E15.5
showing Myf5cre fate map. Myf5 lineage cells are similarly distributed in skeletal
muscles, tail and dorsal tissues of both control (A) and Smyd1 CKO (B) embryos.
Myf5þ cells give rise to dorsal skin and brown adipose, but not ventral skin in both
control (C) and Smyd1 CKO (D) embryos. (E) Western blots using body wall extracts
from E16.5 embryos. Smyd1 protein was undetectable in Smyd1 CKO embryos. Total
myosin heavy chain (MyHC) was reduced in Smyd1 CKO embryos. Anti-β-actin was
used as a loading control. (F, G) Brightﬁeld stereoimages at E15.5. Smyd1 CKO
embryos exhibit subcutaneous edema (white arrow) across the length of the dorsal
side. (H, I) H&E-stained transverse sections (dorsal quarter) at E15.5. A region of
subcutaneous expanded loose connective tissue (black asterisk) is prominent in
Smyd1 CKO embryos. (J, K) Immunoﬂuorescence for α-actinin (red) showing re-
duced abundance of myoﬁbers in Smyd1 CKO embryos at E15.5. Blue, nuclei (DAPI).
White asterisk, subcutaneous edema. Scale bars are 2 mm (A–D, F, G), 500 mm (H, I)
and 100 mm (J, K). BAT, brown adipose tissue; Ctrl, control; CKO, conditional
knockout; MyHC, myosin heavy chain.
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plementary Fig. S1. The abundance of primary and secondary
myoﬁbers was quantiﬁed in transverse EDL sections such as those
illustrated in Fig. 4C, D. Two sections each from nine CKO and ten
control embryos were used for counting and normalized to cross-
sectional area of the muscle. Smyd1 CKOs exhibited signiﬁcantly
fewer primary and secondary ﬁbers as compared to the controls
(Fig. 4E, F). Secondary ﬁber development was impaired more than
primary ﬁber development (22.3% reduction in primary ﬁbers,
44.3% reduction in secondary ﬁbers).
Next, we tested if the loss of myoﬁbers was due to alterations in
expression of myogenic transcription factors. Real-time PCR at
E15.5 showed Pax3, which exhibits relatively higher expression in
embryonic myoblasts and myotubes than in fetal myoblasts and
myotubes (Biressi et al., 2007b), was elevated in the Smyd1 CKO.
Pax7 and Myod1 were unaffected; Myf5 and Myf6 were down-
regulated (Fig. 4G–K). We next examined expression of genesassociated with differentiated skeletal myocytes. mRNA levels of
Acta1 (α-actin), Myh3 (embryonic MyHC), Myh7 (slow MyHC),
Myh8 (fetal MyHC), Ckm (muscle creatine kinase) and Eno3 (β-
enolase) were all reduced in the Smyd1 CKO at E15.5 (Fig. 4L–Q).
These results indicate loss of Smyd1 impairs myoﬁber develop-
ment during the second myogenic wave and support our ob-
servation of fewer muscle ﬁbers in the Smyd1 CKOs at E16.5.
We reasoned that reduced myoﬁber abundance could be the
result of myoﬁber degeneration. To this end, we measured the
width of the myosin ring surrounding nuclei of primary ﬁbers and
expression of atrophy-associated genes Trim63/Murf1 and Fbxo32/
MAFbx/Atrogin1. There was no difference in myoﬁber width
(Fig. 4R) nor in expression of Trim63 or Fbxo32 (Fig. 4S, T). These
data indicate that reduced myoﬁber abundance was not due to
degeneration.
2.6. Loss of Smyd1 impairs myoblast differentiation
Next, we tested whether the reduction in myoﬁbers was due to
alterations in myoblast proliferation, differentiation or induced cell
death. Transverse sections of E11.5 embryos at the depth of the
forelimb bud were immuno-stained for Pax7. The myotomes of
control and Smyd1 CKO embryos displayed equivalent abundance
of Pax7þ cells (Fig. 5A, B). The number of Pax7þ cells were
counted and normalized with respect to total myotome nuclei. We
found no difference in the number of Pax7-expressing myoblasts
between control and Smyd1 CKO embryos during the ﬁrst wave of
myogenesis (Fig. 5C). At E15.5, during the second wave of myo-
genesis, we performed a similar experiment using transverse
sections of EDL muscles. Again, we observed no difference in the
abundance of Pax7þ cells within EDL cross-sections (Fig. 5D, E).
Quantiﬁcation of the percentage of Pax7þ cells conﬁrmed that
conclusion (Fig. 5F). However, comparison of the total number of
myoﬁbers relative to the number of Pax7þ cells indicated that
fewer myoﬁbers arose from approximately the same number of
Pax7þ myogenic progenitor cells in the Smyd1 CKO (Fig. 5G). We
next utilized expression of YFP from the Rosa26YFP allele to com-
pare the number of myoﬁbers relative to non-myoﬁber Myf5
lineage cells (myoblasts) in EDL cross-sections (Fig. 5H, I). We
found a signiﬁcant decrease in the number of myoﬁbers per
myoblast (Fig. 5J).
To determine if the observed reduction in Smyd1 CKO myoﬁber
density resulted from a myoblast proliferation defect, pregnant
mice carrying E15.5 embryos were administered BrdU four hours
prior to sacriﬁce. Proliferating myoblasts were identiﬁed by co-
localization of BrdU and YFP in cross-sections of EDL muscle
(Fig. 5K, L), and quantiﬁed as the percentage of total nuclei within
the EDL (Fig. 5M). We observed no signiﬁcant difference in pro-
liferation rates between control and Smyd1 CKO myoblasts. We
then tested the most likely alternative explanation, apoptosis.
TUNEL assays using E15.5 EDL cross-sections, however, identiﬁed
very few (1-2/section) apoptotic cells in either control or Smyd1
CKO embryos (Fig. 5N, O). In summary, we found reduced myoﬁber
abundance in the presence of comparable numbers of Pax7þ
myogenic precursor cells with no alterations in proliferation or
apoptosis. These data implicated a downstream defect in myoblast
differentiation. To test for a differentiation defect, we assayed the
abundance of Myogþ cells (Fig. 5P, Q) and found a signiﬁcant in-
crease in the percentage of Myogþ cells within the EDL muscle of
Smyd1 CKO embryos (Fig. 5R). These data indicate that Smyd1
affects late stage myoblast differentiation.
2.7. Smyd1 knockdown in C2C12 myoblasts impairs fusion and
blocks myotube hypertrophy
We employed the C2C12 mouse myoblast cell line to determine
Fig. 4. Fewer muscle ﬁbers and reduced muscle gene expression during second wave myogenesis. (A–D) Immunoﬂuorescence for myosin heavy chain (red) in longitudinal
(A, B) and transverse (C, D) sections of the EDL muscle at E16.5. Blue, nuclei (DAPI). White arrowhead, primary myoﬁber; green arrowhead, secondary myoﬁber. (E, F)
Quantiﬁcation of the number of primary (E) and secondary (F) myoﬁbers in the EDL. Smyd1 CKO EDL exhibited less primary and secondary ﬁbers than controls (nZ9
embryos/group). (G–K) Expression of myogenic transcription factor genes in the body wall at E16.5 by real-time PCR (n¼8 embryos/group). (L–Q) Real-time PCR assays for
genes expressed in differentiated myoﬁbers (n¼8 embryos/group). (R) Thickness of myosin ring surrounding nuclei of primary ﬁbers. No difference was observed (nZ5
embryos/group). (S, T) Real-time PCR assays for atrophy genes in the body wall at E16.5. No difference was observed (n¼8 embryos/group). *Po0.05, **Po0.01, ***Po0.001,
Student’s t test. Error bars indicate SEM. Scale bars are 50 μm. Ctrl, control; CKO, conditional knockout.
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Previous studies reported that expression of Smyd1 increases
during myoblast differentiation (Li et al., 2009; Sims et al., 2002).
First, we conﬁrmed these reports by comparing Smyd1 protein
levels in undifferentiated myoblasts vs. differentiated myotubes.
Smyd1 protein was below the detectable threshold in un-
differentiated myoblasts, but steadily increased after 1–5 days in
differentiation medium (Fig. 6A). To reduce Smyd1 levels, C2C12
myoblasts were infected with lentivirus expressing shRNA against
Smyd1 or a non-speciﬁc control shRNA. After ﬁve days in differ-
entiation medium, Smyd1 protein levels were reduced in two in-
dependently derived C2C12 clones that received Smyd1 shRNA
(1.5-fold and 3.1-fold, respectively). The clone that received the
control lentivirus expressed Smyd1 at a similar level to that of the
parental cell line (Fig. 6B). These clones were allowed to undergo
differentiation for ﬁve days and then immuno-stained with a pan-
MyHC antibody. Smyd1 knockdown resulted in thin, hypotrophic
myotubes (Fig. 6C, D). Myotube hypertrophy, as quantiﬁed by
measuring myotube width at widest point on the myotube
(n¼35–60 myotubes/group three technical replicates), was sig-
niﬁcantly decreased in cells that received shRNA against Smyd1(Fig. 6F). As revealed by the distribution of myotubes plotted ac-
cording to their width (Fig. 6G), Smyd1 knockdown cell lines
showed an increased number of small diameter myotubes. Next, a
myoblast fusion index was calculated by dividing the number of
nuclei incorporated into myotubes by the total nuclei in each ﬁeld
of view. Smyd1 knockdown resulted in signiﬁcantly fewer nuclei
integrated into myotubes (Fig. 6E). These data indicate that Smyd1
regulates both myoblast fusion and myotube hypertrophy and
support our in vivo observation of impaired myoblast differentia-
tion in the Smyd1 CKO.3. Discussion
3.1. Spatial and temporal expression of Smyd1 during myogenesis
Previous reports of Smyd1’s subcellular localization during
myoblast differentiation have been limited to endogenous Smyd1
in C2C12 cells and transgenic expression of Myc-tagged Smyd1 in
zebraﬁsh. In C2C12 cells, Smyd1 shuttles from the nucleus to the
cytoplasm during myoblast differentiation (Berkholz et al., 2014;
Fig. 5. Loss of Smyd1 impairs myoblast differentiation. (A–C) Comparison of the number of Pax7þ cells in the myotome at E11.5. (A, B) Representative images of Pax7
immunoﬂuorescence (red). No difference was observed in the percentage of Pax7þ cells in the myotome (nZ5 embryos/group) (C). (D–G) Comparison of the number of
Pax7þ myoblasts in the EDL muscle at E15.5. (D, E) Representative images of Pax7 immunoﬂuorescence (red). Green, myoﬁbers (autoﬂuorescence). No difference was
observed in the percentage of Pax7þ cells in the EDL (F); however, Smyd1 CKO muscle exhibited less myoﬁbers per Pax7þ cell (G) (nZ6 embryos/group). (H–J) Comparison
of the number of ﬁbers relative to myoblasts in the EDL muscle at E15.5. Myoblasts were identiﬁed as non-myoﬁber YFPþ cells. YFP expression is the result of recombination
of the Rosa26YFP allele byMyf5cre and represents theMyf5 lineage. (H, I) Representative images of immunoﬂuorescence for YFP (green) and MyHC (red). (J) Smyd1 CKO muscle
exhibited less myoﬁbers per myoblast (nZ5 embryos/group). (K–M) Comparison of myoblast proliferation within the EDL at E15.5. BrdU was administered 4 h prior to
sacriﬁce. (K, L) Representative images of YFP (green) and BrdU (red) immunoﬂuorescence. No difference was observed in the percentage of BrdUþ myoblasts (double positive
cells) (M) (nZ5 embryos/group). (N, O) Comparison of apoptosis within the EDL at E15.5 by TUNEL assay (red). No difference was observed (nZ5 embryos/group). (P–R)
Comparison of the number of Myogþ cells in the EDL at E16.5. (P, Q) Representative images of Myog immunoﬂuorescence (red). Smyd1 CKO exhibited a higher percentage of
Myogþ cells than controls (R) (n¼6 embryos/group). Blue, nuclei (DAPI). Scale bars are 50 μm (A, B, D, E, N, O) and 20 μm (H, I, K, L, P, Q). *Po0.05, **Po0.01, Student’s t test.
Error bars indicate SEM. Ctrl, control; CKO, conditional knockout; YFP, yellow ﬂuorescent protein; MyHC, myosin heavy chain; BrdU, bromodeoxyuridine; TUNEL, terminal
deoxynucleotidyl transferase dUTP nick end labeling.
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marily cytosolic localization in both myoblasts and myotubes (Li
et al., 2011). For C2C12 cells, we found Smyd1 to be both nuclear
and cytoplasmic in myoblasts, but primarily cytoplasmic in myo-
tubes. Importantly, we found that in vivo, as with C2C12 cells,
Smyd1 protein localized to both the nucleus and cytoplasm of
Myogþ myoblasts within the myotome. Little to no Smyd1 was
detectable in Pax7þ myogenic progenitor cells and Myogþ cells
could be found with or without Smyd1 expression. These ob-
servations indicate that Smyd1 is downstream of Myog, becoming
expressed in differentiating myoblasts. Importantly, this is the
myogenic stage affected by the absence of Smyd1. Smyd1 CKO
embryos exhibited increased Myogþ myoblasts and fewer myoﬁ-
bers. In differentiated muscle ﬁbers, Smyd1 primarily localized to
the sarcoplasm. Within the sarcoplasm, Smyd1 localized within
bands opposite/non-overlapping to that of α-actinin, consistent
with previous reports of Smyd1’s localization to the sarcomeric
M-line in zebraﬁsh fast-twitch muscles (Just et al., 2011; Li et al.,
2011).
Not only does Smyd1’s subcellular localization change during
myoblast differentiation, but protein levels also greatly increase
and most (if not all) of the extra protein ends up in the sarcoplasm.The large increase in Smyd1 protein expression during differ-
entiation is most apparent in western blots, where levels are al-
most undetectable in undifferentiated C2C12 myoblasts and ex-
tremely abundant after a few days in differentiation medium
(Fig. 6A). This is also supported by immunoﬂuorescence experi-
ments because exposure times to detect Smyd1 in myotubes/ﬁbers
are much shorter than for myoblasts (Fig. 1P vs. F and K). Fur-
thermore, when differentiated C2C12 cells are stained for Smyd1,
the undifferentiated myoblasts in the culture appear negative
because of the high abundance in the myotubes (Fig. 1D). Nuclear
Smyd1 is barely detectable in myotubes/ﬁbers in vivo or in vitro;
however there appears to be low nuclear levels that are difﬁcult to
detect due to the high abundance in the sarcoplasm. Collectively,
these observations support the idea that Smyd1 is both an epi-
genetic modulator of transcription as well as a sarcoplasmic reg-
ulator of myoﬁbrillogenesis.
3.2. Defective second wave myogenesis
No gross abnormalities, changes in gene expression or abun-
dance of Pax7þ myoblasts were detected in Smyd1 CKO embryos
at E11.5 (Fig. 2 and Fig. 5A–C) Hence, Smyd1 deletion did not
Fig. 6. Smyd1 knockdown in C2C12 myoblasts impairs fusion and blocks myotube hypertrophy. (A, B) Western blots. Smyd1 protein expression increased throughout the
course of myoblast differentiation (A). Smyd1 protein levels were reduced in cell lines stably expressing shRNA against Smyd1 (B). The C2C12 lane contains extract from the
parental cell line. The Ctrl lane contains extract from a cell line stably expressing non-speciﬁc control shRNA. (C, D) Knockdown of Smyd1 led to thinner myotubes.
Representative images of C2C12 cells expressing control shRNA (C) or Smyd1 shRNA (D) after 5 days in differentiation medium. Myotubes were identiﬁed by immuno-
ﬂuorescence for myosin heavy chain (green). Blue, nuclei (DAPI). (E) Smyd1 knockdown impaired myoblast fusion. Myoblast fusion index was calculated by dividing the
number of nuclei within myotubes by the total number of nuclei (n¼9 replicates/group). (F, G) Smyd1 knockdown impaired myotube hypertrophy. Mean myotube width
(F) and distribution of myotube widths (G) (n¼18 replicates/group). *Po0.05, Student’s t test. Error bars indicate SEM. Scale bars are 100 mm. Ctrl, control; CKO, conditional
knockout; Diff., differentiation; KD, knockdown.
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E10.5 to E12.5 in mice (Biressi et al., 2007b). However, we found
reduced numbers of myoﬁbers as well as altered gene expression
for a number of skeletal muscle speciﬁc genes during the second
myogenic wave, which occurs from E14.5 to E17.5 (Biressi et al.,
2007b). Smyd1 CKO embryos exhibited a greater loss of secondary
than primary myoﬁbers during the second myogenic wave. This
may be due to unique functions for Smyd1 in fast-twitch ﬁbers.
Based on contractile protein expression, previous literature sug-
gests that primary myoﬁbers are similar to adult slow-twitch ﬁ-
bers and secondary ﬁbers are more akin to adult fast-twitch ﬁbers
(Biressi et al., 2007b). Smyd1 mutant zebraﬁsh exhibit defective
myoﬁbrillogenesis speciﬁcally in fast-twitch ﬁbers (Just et al.,
2011). Likewise, CKO of Smyd1 in differentiated myoﬁbers(perinatal CKO post-myogenesis) results in centronuclear myo-
pathy speciﬁcally in fast-twitch muscles (Stewart et al., 2016
(manuscript in review)). Our observation that loss of Smyd1 more
greatly disrupted formation of secondary ﬁbers supports the idea
that Smyd1 may be more important for the stability and/or func-
tion of fast-twitch ﬁbers. These data suggest that although Smyd1
is expressed in all ﬁber types in mammals, it may perform selec-
tive functions in different ﬁber types. Smyd1’s fast-twitch ﬁber-
speciﬁc functions may be more critical for the growth and survival
of myoﬁbers during myogenesis.
We also noticed partial penetrance of the phenotype in Smyd1
CKO embryos in terms of reduction in primary and secondary
muscle ﬁbers during the second myogenic wave. A few CKOs had a
very severe loss of muscle ﬁbers; most CKOs had a modest but
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ferences in the timing of Smyd1 deletion or variability in the
percentage of myoblasts harboring a total loss of Smyd1. The mice
used for this study were of a mixed B6;129 genetic background,
which could conceivably contribute to this variability.
Our evidence suggests Smyd1 is important for late-stage
myoblast differentiation. Both control and Smyd1 CKO muscles
exhibited similar abundance of Pax7þ myogenic progenitor cells,
rates of proliferation and apoptosis in the EDL at E15.5, the mid-
point of the second myogenic wave. We found no evidence for
degeneration as Smyd1 CKOs did not exhibit TUNEL positive
myoﬁbers, alterations in atrophy gene expression or reduction in
myoﬁber diameter. What we did ﬁnd was fewer myoﬁbers relative
to myoblasts and increased numbers of Myogþ myoblasts. These
data suggest impaired myoblast differentiation and are consistent
with the impaired myoblast fusion observed for Smyd1 knock-
down C2C12 cells.
The stage in mouse embryogenesis when motor neurons ﬁrst
make contact with developing muscle ﬁbers is also during the
second myogenic wave (Rossi and Messina, 2014). Interaction be-
tween newly forming muscle ﬁbers and neurons is necessary for
further development of myoﬁbers. Failure of motor neurons to
properly interact with developing myoﬁbers leads to dis-integra-
tion of both primary and secondary muscle ﬁbers, with the latter
being more severely affected (Biressi et al., 2007a). This phenotype
is very similar to what we observe in our Smyd1 CKO mouse em-
bryos. Hence it is possible that Smyd1 plays a role in relaying a
survival cue from newly formed neuromuscular junctions. How-
ever, data from C2C12 cells argues against this being the primary
defect. Knock-down of Smyd1 expression in C2C12 cells led to
hypotrophic, poorly differentiated myotubes with reduced fusion
index and impaired myoﬁber growth. These in vitro data do not
support the idea that myoﬁber loss was due to negative effects on
innervation, but rather due to intrinsic effects on myoblast dif-
ferentiation or myoﬁber growth. It appears from immuno-
ﬂuorescence experiments that individual Smyd1 CKO myoﬁbers
contain less total MyHC protein (CKO myoﬁbers exhibit weaker
anti-MyHC ﬂuorescence intensity than control myoﬁbers)
(Fig. 4A–D and Supplementary Fig. S1). This observation implicates
Smyd1 as a positive regulator of muscle gene expression under-
lying myoﬁber growth.
Smyd1 CKO embryos showed altered expression of three major
myogenic transcription factors (Pax3, Myf5 and Myf6) only during
the second wave of myogenesis (Fig. 4G, I, K). Reduced Myf5 ex-
pression, which is temporally downstream of Pax7 during myo-
genesis, indicates that there may be a defect in myoblast differ-
entiation or that Smyd1 regulates the myoblast differentiation
gene expression program. Reduced expression of Myf5 was not the
result of the Myf5cre knock-in because our control embryos also
expressed cre (Controls were Myf5cre/þ ; Smyd1ﬂox/þ). Increased
expression of Pax3 could be due to a compensatory feedback loop
due to impaired myoblast differentiation. Pax3 is more highly ex-
pressed in primary wave myoblasts and myoﬁbers than in their
secondary wave counterparts (Biressi et al., 2007b). Thus, in-
creased Pax3 expression opens the possibility that Smyd1 CKO fetal
myoblasts retain the gene expression signature of embryonic
myoblasts, which may impair second wave myogenesis. Alter-
natively, increased Pax3 could simply reﬂect the increased ratio of
primary to secondary myoﬁbers. Myf6 is expressed late during
myogenesis and it is the only MRF expressed in mature myoﬁbers
(Rhodes and Konieczny, 1989). Reduced Myf6 expression would
impair myoﬁber development, as seen in the Smyd1 CKO; how-
ever, decreased Myf6 mRNA could be a consequence of less total
myoﬁbers.
In zebraﬁsh embryos, Smyd1 knockdown did not affect the
mRNA levels of slow and fast myosin isoforms, but did affect theirprotein levels (Li et al., 2013). It was apparent from anti-MyHC
immunoﬂuorescence that Smyd1 CKO myoﬁbers have less total
MyHC protein than controls (Fig. 4A–D and Supplementary Fig.
S1). Thus, our data are consistent with those from zebraﬁsh
models, in that loss of Smyd1 resulted in reduced MyHC protein;
however, we also observed reduced gene expression for several
MyHC isoforms (Myh3, Myh7 and Myh8) and α-actin (Acta1)
(Fig. 4M–P). These alterations in gene expression could be a con-
sequence of fewer myoﬁbers, but also support the idea that Smyd1
positively regulates contractile protein gene expression. The latter
hypothesis is supported by a recent article indicating that Smyd1
is essential for activation of muscle genes in rhabdomyosarcoma
(Coda et al., 2015).
3.3. Edema and embryonic lethality
Smyd1 CKO embryos are motionless when recovered on E17.5
or E18.5 and consistently die perinatally (Table 1). A very similar
phenotype, including dorsal subcutaneous edema and perinatal
lethality, was observed when Smyd1 was deleted using Myog-cre,
(Rasmussen and Tucker, unpublished observations). These data
indicate that muscle contraction becomes impaired over time—
essentially a mild version of the phenotype reported for zebraﬁsh
Smyd1 mutants or knock-downs where muscle contraction was
completely absent from myoﬁber inception (Just et al., 2011).
Failed myoﬁbrillogenesis in zebraﬁsh is thought to result from
improper myosin folding or assembly (Just et al., 2011).
Almost all Smyd1 CKOs exhibited subcutaneous edema re-
miniscent of the “amorphous connective tissue” reported for the
Myf5/MyoD double knock-out mouse (Rudnicki et al., 1993), which
completely lacks skeletal muscle. Thus, subcutaneous edema could
be the consequence of muscle loss. Edema could also be the con-
sequence of impaired circulation or lymphatic drainage. This is
puzzling as Smyd1 expression is restricted to striated muscles and
CD8þ T lymphocytes (Gottlieb et al., 2002; Hwang and Gottlieb,
1997). Myf5þ progenitors give rise to skeletal muscle, brown
adipose, some rib cartilage, dorsal skin and connective tissues
((Haldar et al., 2008) and Fig. 3C, D). Thus, vessels along the dorsal
aspect of the embryo could be impacted by Myf5cre. But, even if
Myf5cre catalyzed Smyd1 deletion in other tissues, it is unlikely to
have an effect because Smyd1 is not expressed in those tissues.
This suggests depletion of Smyd1 from the skeletal muscle lineage
has a non-cell autonomous effect on the circulatory/lymphatic
system. We looked for heart defects, but found no obvious mor-
phological abnormalities by histological analysis and there was no
pericardial edema (data not shown). Although the striated muscle-
speciﬁc expression pattern is well-documented, Smyd1 could be
expressed in a non-muscle cell type that is also in theMyf5 lineage
and important for proper circulation (e.g. dorsal smooth muscle or
endothelial cells). The other members of the SMYD family (Smyd2
- 5) exhibit broad expression in many cell types. Thus, it is not
unreasonable to hypothesize that Smyd1 expression is broader
than currently known.
Collectively, our results indicate that inception of the skeletal
myogenesis program does not require Smyd1, but downstream
events do. Elimination of Smyd1 impairs myoﬁber development
and alters myogenic gene expression during the second wave of
mammalian skeletal myogenesis. In zebraﬁsh, Smyd1 is only cri-
tical for sarcomerogenesis in fast-twitch myoﬁbers (Just et al.,
2011). In contrast, in mice, where both fast- and slow-twitch ﬁbers
are multi-nucleated and interspersed, Smyd1 appears to be ne-
cessary for proper development of both ﬁber types during em-
bryogenesis. Based on our studies and the current literature,
Smyd1 is multi-functional and vital for diverse aspects of muscle
biology via epigenetic effects on gene expression and protein–
protein interactions that facilitate myoﬁbrillogenesis. A
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regions targeted by Smyd1 histone methyltransferase action and
to determine the accompanying epigenetic consequences in vivo.4. Materials and methods
4.1. Animals
Smyd1ﬂox/ﬂox mice were developed in collaboration with Dr.
Haley Tucker (University of Texas, Austin) (Rasmussen et al., 2015).
Smyd1þ / mice were generated by crossing Smyd1ﬂox/ﬂox to the
maternal deleter Tg(Sox2-cre) (Hayashi et al., 2003) (Jackson La-
boratory, stock #8454). Rosa26YFP/YFP and Myf5cre/þ mice were
obtained from the Jackson Laboratory (stock #7903 and #10529,
respectively). Mice for experimental analysis were obtained from
the following cross: Myf5cre/þ ; Smyd1þ / x Smyd1ﬂox/ﬂox;
Rosa26YFP/YFP. Controls were Myf5cre/þ ; Smyd1ﬂox/þ ; Rosa26YFP/þ .
CKOs were Myf5cre/þ ; Smyd1ﬂox/-; Rosa26YFP/þ .
The following primers were used for genotyping: Cre-F: 5′-GCC
ACC AGC CAG CTA TCA ACT C, Cre-R: 5′-TTG CCC CTG TTT CAC TAT
CCA G, Smyd1-F: 5′-TCA TGA GAT GGG CAT GAG CC, Smyd1-R1 5′-
GCA TAC GCA CAT GTG CTC GC, Smyd1-R2: 5′-CTC ACT TGC GTC
CCA GTA CTT G. Smyd1-F/R1 identiﬁes wild-type and ﬂox alleles
(432 bp and 552 bp, respectively). Smyd1-F/R2 identiﬁes the null
allele (500 bp). Mice were euthanized by CO2 inhalation fol-
lowed by cervical dislocation. All experimental procedures invol-
ving mice were approved by the Institutional Animal Care and Use
Committee of the University of Houston.
4.2. Tissue collection
Embryos were manually dissected in PBS immediately after
euthanasia. For RNA or protein extraction, tissues were snap frozen
in liquid nitrogen and stored at 80 °C. For H&E staining, tissues
were ﬁxed by overnight immersion in Bouin’s ﬂuid. For im-
munoﬂuorescence, tissues were ﬁxed overnight in 4% PFA in PBS
and rinsed in 70% ethanol for Z25 h prior to tissue processing. All
tissues were dehydrated through a standard ethanol gradient,
cleared in Histoclear (National Diagnostics, cat# HS-200) and
embedded in Paraplast Pluss Tissue Embedding Medium (Statlab,
cat# 2004). Seven to eight micron sections were prepared for
histology.
4.3. Wholemount in situ hybridization
Wholemount in situ hybridization was performed following a
standard protocol (Nagy, 2003). Digoxigenin (DIG)-labeled com-
plementary RNA probes were prepared using a DIG RNA Labeling
Kit (Roche, cat# 11 175 025 910). Hybridization and wash steps
were automated using an InsituPro robot (Intavis AG). Hybridized
probes were visualized by a color reaction using alkaline phos-
phatase-conjugated anti-DIG Fab fragments (Roche, cat# 11 093
274 910) and nitroblue tetrazolium and bromochloroindolyl
phosphate (NBT-BCIP) reagents (Roche, cat# 11 681 451 001).
Embryos were post-ﬁxed in 4% paraformaldehyde-PBS and imaged
in PBS. Probe sequence information is available upon request.
4.4. Western blotting
Western blot assays were carried out with either C2C12 whole
cell extracts obtained using RIPA buffer or frozen E16.5 embryos
with head and internal organs removed homogenized in T-PER
buffer (Life Technologies) according to the manufacturer’s in-
structions. Lysis buffers were supplemented with protease and
phosphatase inhibitors. The cell lysate was centrifuged at 10,000 xg for 5 min. 50 μg of supernatant protein was solubilized in
Laemmli Buffer and separated by 4–20% SDS-PAGE (Mini Protean II
System, Bio-Rad Laboratories, Hercules, CA). The proteins were
transferred onto 0.2 μm nitrocellulose membranes (Bio-Rad La-
boratories). Membranes were blocked with 5% non-fat milk-TBST
for 1 h at room temperature. Primary antibodies recognizing
Smyd1 (Santa Cruz, cat# sc-79080), MyHC (Developmental Studies
Hybridoma Bank, clone MF-20) or β-actin-HRP (Santa Cruz I-19,
cat# sc-1616) were diluted in 2.5% non-fat milk-TBST. Following
overnight incubation at 4 °C with primary antibody, membranes
were washed with TBST and then incubated with the appropriate
horseradish peroxidase-conjugated secondary antibody for 3 h at
room temperature. Membranes were washed again, and visualized
by chemiluminescence using SuperSignal West Pico Chemilumi-
nescent Substrate (Thermo Scientiﬁc, Rockford, IL). Mean pixel
intensity of western blot band was calculated using ImageJ soft-
ware v1.48 (National Institutes of Health, USA).
4.5. Histological analyses
H&E staining was performed using a standard protocol. Im-
munoﬂuorescence was performed on 8 μm parafﬁn sections using
1x casein-PBST (Vector Labs) for blocking and 10% normal serum
(Vector Labs) in PBST as the antibody diluent. Primary antibodies
were incubated overnight at 4 °C. Secondary antibodies were in-
cubated for 1 h at room temperature. All slides were counter-
stained with DAPI and coverslips mounted with Vecta-Shield hard
set mounting medium (Vector Labs). Primary antibodies used were
as follows: Smyd1 (Santa Cruz, cat# sc-79080), MyHC (Develop-
mental Studies Hybridoma Bank, clone MF-20), α-actinin (clone
EA-53, Sigma-Aldrich, cat# A7811), GFP (Abcam, cat# ab6662) and
Pax7 (Developmental Studies Hybridoma Bank).
To assay cell proliferation, pregnant mice were weighed and
injected with 10 ml/kg BrdU Labeling Reagent (Invitrogen, cata-
log# 00-0103) 4 h before sacriﬁce. Immunoﬂuorescence was per-
formed as described above with anti-BrdU monoclonal antibodies
(Developmental Studies Hybridoma Bank, clone G3G4). Apoptosis
was assayed using the Click-iT s Plus TUNEL Assay kit (Life tech-
nologies, Catalog#C10618) according to the manufacturer’s
instructions.
4.6. Microscopy
Stereoimages (brightﬁeld and ﬂuorescence) were captured
with a Leica MZ10F stereomicroscope and the extended depth of
focus feature of LAS v3.7 software (Leica Microsystems, Wetzlar,
Germany). Brightﬁeld and epiﬂuorescence images of tissues sec-
tions were obtained using a Nikon Ti-E inverted microscope
equipped with a DS-Fi1 5-megapixel color camera (Nikon Instru-
ments), a CoolSNAP HQ2 14-bit monochrome camera (Photo-
metrics, Tucson, AZ) and NIS Elements software v4.13 (Nikon
Instruments).
4.7. Real-time PCR
Total RNA was extracted from whole E11.5 embryos or E15.5
embryos with head and internal organs removed using TRIzol
reagent according to the manufacturer’s protocol (Life Technolo-
gies, Carlsbad, CA). mRNA levels were measured using TaqMan
gene expression assays with 6-carboxyﬂuorescein (FAM)-labeled
probes from Applied Biosystems (Life Technologies)
(Mm01332463_m1 for Myh3, Mm01319006_g1 for Myh7,
Mm01329494_m1 for Myh8, Mm01203489_g1 for Myod1,
Mm01354484_m1 for Pax7, Mm00468267_m1 for Eno3,
Mm01321487_m1 for Ckm,Mm00808218_g1 for Acta1,
Mm01185221_m1 for Trim63, Mm00499523_m1 for Fbxo32) and
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Pax3-R: 5′-GTT GAT TGG CTC CAG CTT GTT T, Pax3-Probe: 5′-TCT
GGT TTA GCA ACC GCC GTG CA), Myf5 (Myf5-F: 5′- AGC AGC TTT
GAC AGC ATC TAC TGT, Myf5-R: 5′-AAT GCT GGA CAA GCA ATC
CAA, Myf5-Probe: 5′-TGC TGC AGA TAA AAG CTC CGT GTC CA) and
Myf6 (Myf6-F: 5′- AGC TAC AAA CCC AAG CAA GAA ATT, Myf6-R:
5′-CCT GGA ATG ATC CGA AAC ACT T, Myf6-Probe: 5′-TGC GGA TTT
CCT GCG CAC CTG) (Biosearch Technologies, Petaluma, CA). The
level of GapdhmRNAwas used for normalization. The PCR was run
using an ABI Prism 7900HT thermocycler and SDS2.1 software
(Applied Biosystems). Data were analyzed by the comparative
ΔΔCT method.4.8. Cell culture
The mouse skeletal myoblast cell line C2C12 was obtained from
ATCC (cat# CRL-1772). C2C12 cells were routinely cultured in their
undifferentiated state in high glucose DMEM supplemented with
20% fetal bovine serum and 1X antibiotic–antimycotic (Life Tech-
nologies, cat# 15240-096) at 37 °C and 5% CO2. Differentiation was
induced by switching the medium to high glucose DMEM sup-
plemented with 2% horse serum and 1 mg/ml insulin after the cells
reached about 90% conﬂuence. Differentiating C2C12 cells were
supplied with fresh differentiation medium every 24 h and
maintained at 37 °C and 5% CO2.
Control and Smyd1 knockdown C2C12 cell lines were generated
using GIPZ lentiviral particles encoding short hairpin-RNA against
Smyd1 (Thermo-scientiﬁc, source clone ID# V3LMM_480880,
V2LMM_61704, V3LMM_480879) and non-silencing control shRNA
(catalog # RHS4348) according to the manufacturer's instructions.
Successfully transduced cells were selected by puromycin
treatment.4.9. Statistical analyses
For studies with two experimental groups, an independent
samples Student’s t-test was performed. Prior to t-test, an F-test
was performed to determine if the variances of the two groups
were equal. If Po0.05 for the F-test (unequal variances), the test
was repeated with log-transformed data. If log-transformed data
showed unequal variances, the t-test was performed with a cor-
rection for unequal variances (Welch test). Embryonic lethality
data (expected vs. observed genotypes) were analyzed by the
Fisher's exact test. A P-value of o0.05 was considered signiﬁcant
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